

Procter & Gamble - I.P. Division**IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this teletype transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this teletype in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.


**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**
TO: - United States Patent and Trademark Office
**RECEIVED
CENTRAL FAX CENTER**

Fax No. 703-872-9306

Phone No.

MAY 02 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on May 8, 2005, to the above-identified facsimile number.



(Signature)

FROM: Linda S. Jernigan (Typed or printed name of person signing Certificate)

Fax No. 513-622-3300

Phone No. 513-622-2811

Listed below are the item(s) being submitted with this Certificate of Transmission:**

- 1) Supplemental IDS – 4 pgs. – orig. w/copy
- 2) PT0SB08 – 1 pg. – orig. w/copy
- 3) Copy of Reference – 6 pgs.
- 4)
- 5)

Number of Pages Including this Page: 17

Inventor(s): Pithal.

S.N.: 09/950052

Filed: September 12, 2001

Docket No.: P164R&*

Comments:

**Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

Certification of Mailing or Facsimile Transmission
 I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being submitted as indicated below:
 I mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____ Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450
 I facsimile transmitted to the U.S. Patent and Trademark Office via fax number (703) 872-9366

Linda S. German	Registration No. (if applicable)
<i>Linda S. German</i>	
May 2, 2005	Date

RECEIVED
 CENTRAL FAX CENTER

MAY 02 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/950052
 Applicant(s) : Pitha et al.
 Filed : September 12, 2001
 Title : Mimicking The Metabolic Effects Of Caloric Restriction By Administering Glucose Antimetabolites
 TC/A.U. : 1651
 Examiner :
 Conf. No. : 9900
 Docket No. : P164R&
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

OR

All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ___, filed ___. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

It is respectfully requested that the Examiner consider and make of record the co-pending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Kelly L. McDow-Dunham

Typed or printed name

Registration No. 43,787
(513) 622-0159

Date: May 2, 2005
Customer No. 27752
(IDS.doc) (Last Revised 4/11/2005)

Please type a plus sign (+) inside this box → [+]

SUPPLEMENTAL PTO/SB08A (08-03)

Under the Paperwork Reduction Act of 1995, no persons
Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

SHEET 1 of 1

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
pertinent. Include copy of this form with next communication to applicant. MPEP 601.04. ³Enter Office that

considered. Include copy of this form with next communication to Applicant.
1 Applicant's unique citation designation number (optional).² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document by the two-letter code (WIPO Standard ST.3).³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTD-SH08 (Revised for P&G use 11/5/2004)

Certification of Mailing or Facsimile Transmission I hereby certify that I have reasonable basis to expect that, on the date above below, the correspondence is being submitted as indicated below: <input type="checkbox"/> mailed or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 <input checked="" type="checkbox"/> facsimile transmitted to the U.S. Patent and Trademark Office via fax number (703) 972-9306	
Linda S. Jernigan <small>Reg. No. _____</small>  <small>May 2, 2001</small> <small>Signature</small> <small>May 2, 2001</small> <small>Date</small>	

RECEIVED
CENTRAL FAX CENTER

MAY 02 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 09/950052
 Applicant(s) : Pitha et al.
 Filed : September 12, 2001
 Title : Mimicking The Metabolic Effects Of Caloric Restriction By Administering Glucose Antimetabolites
 TC/A.U. : 1651
 Examiner :
 Conf. No. : 9900
 Docket No. : P164R&
 Customer No. : 27752

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. **37 C.F.R. §1.97(b)(1)** - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. **37 C.F.R. §1.97(b)(3)** - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. **37 C.F.R. §1.97(b)(4)** - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). A first Office Action after filing a Request For Continued Examination (RCE) has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. **37 C.F.R. §1.97(c) with fee payment** - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). A final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) has not been received as of the date of this submission. I hereby elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5. Information to be Considered with Continued Prosecution Application (CPA) Filing (use when filing IDS with a Continued Prosecution Application (CPA) for Design Case). This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 C.F.R. 1.53(d).

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

OR

All of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. ____, filed ____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

OR

Copies of all said documents, except Cite Numbers _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Priority is claimed to said application under 35 U.S.C. §120. Accordingly, copies of previously submitted references are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of references not previously submitted are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

It is respectfully requested that the Examiner consider and make of record the co-pending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Kelly L. McDow-Dunham

Typed or printed name

Registration No. 43,787

(513) 622-0159

Date: May 2, 2005
Customer No. 27752
(IDS.doc) (Last Revised 4/11/2005)

Please type a plus sign (+) inside this box → [+]

SUPPLEMENTAL PTO/SB08A (08-03)
U.S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Governmental Record Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no person
Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	
Substitute for form 1449A/PTO	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	
(use as many sheets as necessary)	
SHEET 1 of 1	
COMPLETE IF KNOWN	
Application Number	09/950052
Confirmation Number	9900
Filing Date	September 12, 2001
First Named Inventor	Pitha et al.
Group Art Unit	1651
Examiner Name	
Attorney Docket Number	P164R&*

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.
*Applicant's unique citation designation number (optional). *See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB-08 (Revised for P&G use 11/5/2004)